Comparative analysis of the addition of empagliflozin versus doubling the furosemide dose in decompensated heart failure.
Fuat PolatZeynettin KayaCuma SüleymanoğluPublished in: Cardiovascular drugs and therapy (2024)
This study provides valuable insights into the management of decompensated HFrEF and demonstrates that SGLT2 inhibitors offer benefits beyond glycemic control in this patient group. The significant reduction in rehospitalization rates and improvements in echocardiographic parameters underscore the potential of SGLT2 inhibitors in reducing acute heart failure episodes.
Keyphrases
- heart failure
- acute heart failure
- glycemic control
- left ventricular
- type diabetes
- blood glucose
- cardiac resynchronization therapy
- ejection fraction
- atrial fibrillation
- case report
- pulmonary hypertension
- mitral valve
- left atrial
- metabolic syndrome
- human health
- adipose tissue
- insulin resistance
- skeletal muscle
- risk assessment
- hepatitis b virus